![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, February 08, 2022 1:01:39 PM
ae kusterer Tuesday, 02/08/22 10:55:31 AM
Re: None 0
Post # of 442269
pgsd Tuesday, 02/08/22 10:47:18 AM
Re: None
Post #
442201
of 442205
Another really interesting part of the recently discussed combination patent are the following identified in the 'Detailed description of the invention':-
[0048]
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
[0049]
Before the present compositions and methods are described, it is to be understood that this invention is not limited to particular compositions, methods, and experimental conditions described, as such compositions, methods, and conditions may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only in the appended claims
This opens the invention (and protection) to a very wide area of potential applications should it be awarded. Access the full summary of the invention and look at [0058] and the list of applicable list of cancers given as examples, Completely mind blowing.
ae kusterer Tuesday, 02/08/22 10:12:48 AM
Re: muee88 post# 442145 0
Post #
442187
of 442206
Muee88:If the NWBO combo patent gets awarded, does that in effect extend Keytruda solid tumor patents(which expire in 5 years?) if MRK combines Keytruda with DC VAX L ? Thanks.
ae kusterer Tuesday, 02/08/22 09:42:33 AM
Re: None 0
Post #
442164
of 442183
muee88 Monday, 02/07/22 11:45:00 PM
Re: flipper44 post# 441910 0
Post #
442092
of 442166
NWBO submitted a response on 2/2. The most recent rejection included several ancillary things needing to be taken care of. This looks like it will be allowed now, which is great!
See paragraph 4 in the 4 page document."Argument" .First link below. The patent attorney pleads that all questions and / or objections raised by the patent reviewer have been addressed, and therefore the patent should be awarded.Any patent attorneys present to opine on this?
ae kusterer Monday, 02/07/22 05:44:59 PM
Re: None 0
Post #
442057
of 442146
How close is this application to awarded ?
https://patentcenter.uspto.gov/#!/applications/14533879/ifw/docs ( see 4 pages 2/2/22) (applicant argument) (see "Conclusion")
https://patentcenter.uspto.gov/#!/applications/14533879
ae kusterer Monday, 02/07/22 04:53:46 PM
Re: None 0
Post #
442050
of 442057
flipper44 Member Level Monday, 02/07/22 11:21:32 AM
Re: None 0.110
Post #
441875
of 442049
Very Recent Combination Patent application action:
Application Number: 14/533,879
02-04-2022 CRF Disk Has Been Received by Preexam / Group / PCT
02-02-2022 Substitute Specification Filed
02-07-2022 Date Forwarded to Examiner
02-02-2022 Response after Non-Final Action
02-02-2022 Request for Extension of Time - Granted
02-04-2022 CRF Is Good Technically / Entered into Database
pgsd Tuesday, 02/08/22 07:23:01 AM
Re: flipper44 post# 441910
Post #
442116
of 442155
Thanks Flipper, this is really interesting. In particular. the following:-
Prior Rejections
"Applicant thanks the Examiner for withdrawal of rejection of Claims 1,3,10,11,12,18,19,20,22,29,30,31,33,34,48 and 50 under 35 U.S.C. 103 as being unpatentable over Fadul in view of Jacobs and Dulos as well as the rejection of Claims 1,3,6,10,11,12,18,20,22,25.29-31.33.48 and 50 under 35 103 as being unpatentable over Yamanaka in view of Jacobs and Dulos"
IMO this is a really positive development. What appears to have happened is NWBO has submitted new articles that have convinced the examiner they were wrong in saying the claims were "unpatentable" The fact that the examiner has withdrawn the rejection IMO is huge as they could easily have just stuck with the decision.
Also, two other claims (19 and 34) the examiner states "would be allowable" if rewritten "in independent form including all the limitations of the base claim and any intervening claims"
flipper44 Member Level Tuesday, 02/08/22 05:05:55 AM
Re: flipper44 post# 441875 0
Post #
442097
of 442157
Four days ago: Italian meta-analysis of 15 small trials.
Published February 4, 2022
Quote:
In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf
Quote:
It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.
InvestorsHub NewsWire
Robotic Assistance Devices Shipping Large Quantity of Units as Fiscal Year End Approaches • AITX • Feb 8, 2022 9:48 AM
Oncology Pharma Gives Update on Technology, Formulation and Data Creation • ONPH • Feb 8, 2022 9:30 AM
Ammo Inc. Board Approves up to $30 Million Dollar Repurchase Authorization • POWW • Feb 8, 2022 9:04 AM
Splash Beverage Group Signs Distribution Agreement with Anheuser-Busch Distributor Heimark Distributing for TapouT in Southern California • SBEV • Feb 8, 2022 9:03 AM
Mineworx Pleased with Court Decision • MWX • Feb 8, 2022 9:02 AM
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate • ENVB • Feb 8, 2022 8:48 AM
Research Study Proves Calmer Canine Veterinary Therapy Device Resolves Separation Anxiety in Dogs • ADMT • Feb 7, 2022 2:51 PM
WPUR VERY BULLISH at $0.01 On Electric Utility And EV Charging News • ILST • Feb 7, 2022 2:18 PM
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant - Moves Towards FDA/IND-Submission • IPA • Feb 7, 2022 11:24 AM
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 • RDHL • Feb 7, 2022 11:18 AM
HNRC UPDATES ON 18 MONTHS OF ACCOMPLISHMENTS • HNRC • Feb 7, 2022 11:04 AM
Start posting your company's news. Only $200 per official company press release!
ae kusterer Tuesday, 02/08/22 09:23:59 AM
Re: None 0
Post #
442153
of 442160
See paragraph 4 in the 4 page document."Argument" .First link below. The patent attorney pleads that all questions and / or objections raised by the patent reviewer have been addressed, and therefore the patent should be awarded.Any patent attorneys present to opine on this?
ae kusterer Monday, 02/07/22 05:44:59 PM
Re: None 0
Post #
442057
of 442146
How close is this application to awarded ?
https://patentcenter.uspto.gov/#!/applications/14533879/ifw/docs ( see 4 pages 2/2/22) (applicant argument) (see "Conclusion")
https://patentcenter.uspto.gov/#!/applications/14533879
ae kusterer Monday, 02/07/22 04:53:46 PM
Re: None 0
Post #
442050
of 442057
flipper44 Member Level Monday, 02/07/22 11:21:32 AM
Re: None 0.110
Post #
441875
of 442049
Very Recent Combination Patent application action:
Application Number: 14/533,879
02-04-2022 CRF Disk Has Been Received by Preexam / Group / PCT
02-02-2022 Substitute Specification Filed
02-07-2022 Date Forwarded to Examiner
02-02-2022 Response after Non-Final Action
02-02-2022 Request for Extension of Time - Granted
02-04-2022 CRF Is Good Technically / Entered into Database
pgsd Tuesday, 02/08/22 07:23:01 AM
Re: flipper44 post# 441910
Post #
442116
of 442155
Thanks Flipper, this is really interesting. In particular. the following:-
Prior Rejections
"Applicant thanks the Examiner for withdrawal of rejection of Claims 1,3,10,11,12,18,19,20,22,29,30,31,33,34,48 and 50 under 35 U.S.C. 103 as being unpatentable over Fadul in view of Jacobs and Dulos as well as the rejection of Claims 1,3,6,10,11,12,18,20,22,25.29-31.33.48 and 50 under 35 103 as being unpatentable over Yamanaka in view of Jacobs and Dulos"
IMO this is a really positive development. What appears to have happened is NWBO has submitted new articles that have convinced the examiner they were wrong in saying the claims were "unpatentable" The fact that the examiner has withdrawn the rejection IMO is huge as they could easily have just stuck with the decision.
Also, two other claims (19 and 34) the examiner states "would be allowable" if rewritten "in independent form including all the limitations of the base claim and any intervening claims"
flipper44 Member Level Tuesday, 02/08/22 05:05:55 AM
Re: flipper44 post# 441875 0
Post #
442097
of 442157
Four days ago: Italian meta-analysis of 15 small trials.
Published February 4, 2022
Quote:
In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf
Quote:
It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM